A widely used blood pressure medication may have an unexpected benefit beyond its ability to control hypertension. Scientists have found that losartan can activate brown fat, a specialized type of body fat that burns energy, and improve metabolic activity in mice. The discovery suggests that an existing medication could potentially be repurposed to stimulate brown fat and support metabolic health.
Losartan belongs to a class of medications called angiotensin receptor blockers (ARB), which have an established safety profile. In a new study published in Natureresearchers found that the drug increased brown fat activity through a biological mechanism separate from its blood pressure effects. This raises the possibility of developing treatments that activate brown fat without lowering blood pressure.
The findings also revealed a surprising connection between brown fat and mental health. After examining data from more than 100,000 patients, researchers discovered that people with detectable brown fat had lower rates of several medical conditions, including anxiety and depression. This is the first time the research team has reported associations between brown fat and psychiatric health, adding to earlier evidence linking the tissue to better cardiovascular and metabolic health.
The research was led by Paul Cohen at Rockefeller University’s Laboratory of Molecular Metabolism, working with Heiko Schöder and Daniel Lafontaine from Memorial Sloan Kettering Cancer Center (MSKCC). It expands on research published in 2021when Cohen’s team analyzed approximately 50,000 patients and found that those with more brown fat had substantially lower odds of developing cardiometabolic conditions such as coronary artery disease and type II diabetes.
“We only looked for a few diagnostic codes in that study, mainly focusing on cardiovascular disease since that’s what this tissue has historically been associated with,” says Cohen. “The scope of this new analysis is far more expansive. We doubled our number of patients and considered more than 500 codes, which allowed us to unearth many new insights.”
AI Analysis Reveals New Benefits of Brown Fat
To investigate brown fat’s relationship with human health, the researchers examined PET/CT scans from more than 100,000 patients who had undergone imaging as part of their cancer monitoring. They focused on scans showing brown adipose tissue, which can be found in six regions of the body, including the neck, armpits, and areas around organs such as the heart and kidneys.
The team used an approach known as reverse translation, which begins with observations in patients and then investigates the biological processes responsible for them. Cohen’s laboratory has previously used this strategy to uncover important details about brown fat and its effects on health.
Nicolás Gómez-Banoy, the study’s first author and an endocrinologist and instructor in clinical investigation in Cohen’s laboratory, used a machine learning system developed by researchers at MSKCC to measure brown fat activity. The technology allowed him to assess both the total activity in each patient and the activity within each of the six anatomical regions.
The analysis showed that brown fat’s location could be just as important as its presence. Activity in particular regions appeared to have stronger associations with certain health conditions, suggesting that brown fat may influence the body differently depending on where it is found.
“For example, the axillary, or armpit, area was linked to a decreased risk of high blood pressure compared to other regions,” he says. “But overall, patients with brown fat have better glycemic parameters, lipid profiles, and echocardiographic indices, as well as lower inflammatory markers.”
These findings indicate that people with brown fat tend to have healthier blood sugar levels, blood fat profiles, measures of heart function, and indicators of inflammation.
Common Blood Pressure Drug Activates Brown Fat
As the researchers investigated medications associated with brown fat activity, they noticed an intriguing pattern. Patients taking angiotensin receptor blockers were more likely to have detectable brown fat on their scans, suggesting that these widely prescribed medications might influence the tissue.
To explore that possibility, the team conducted laboratory experiments using cultured brown fat cells. They found that losartan directly increased the cells’ metabolic activity, providing evidence that the drug could stimulate brown fat rather than simply being associated with its presence.
Even more interestingly, the researchers discovered that losartan activated brown fat through molecular pathways different from those responsible for lowering blood pressure. That distinction could be especially valuable for developing future medications that target metabolism without interfering with normal blood pressure regulation.
“The fact that its different effects are mediated by different molecular pathways is advantageous, since it means we could potentially isolate them in future therapies,” says Gómez-Banoy. “That way you would be able to stimulate brown fat in people with normal blood pressure.”
Additional experiments in healthy mice strengthened the findings. Animals given losartan showed increased energy expenditure, consumed more oxygen, and produced more carbon dioxide, all signs of heightened metabolic activity. Despite these changes, their body weight remained stable.
Brown Fat’s Surprising Connection to Mental Health
Beyond its metabolic effects, brown fat may have a previously unrecognized relationship with psychological well-being. The patient analysis revealed that individuals with detectable brown fat had lower rates of anxiety and depression, extending the tissue’s potential health associations beyond the cardiovascular system.
“We know that metabolically healthy people tend to have lower incidence of psychiatric diseases, so it could be that having brown fat makes you more metabolically healthy, and this correlates with fewer psychiatric issues,” says Gómez-Banoy.
The researchers also found an intriguing relationship involving selective serotonin reuptake inhibitors, or SSRIs, medications commonly prescribed to treat depression. These drugs appeared to suppress brown fat activity, suggesting another possible connection between psychiatric treatments and metabolic regulation.
However, the findings do not suggest that brown fat is beneficial in every respect. The analysis also identified higher rates of osteoporosis and certain skin diseases among people with brown fat, raising questions about possible trade-offs that require further investigation.
The discoveries have opened several avenues for future research. Scientists hope to examine the genetics of people with particularly high brown fat activity, investigate why the tissue is associated with lower rates of anxiety and depression, and determine whether its apparent benefits can be harnessed safely.
Losartan may also be only one of several existing medications worth investigating. The extensive patient analysis identified additional drugs associated with brown fat activity, offering researchers a range of potential candidates for future studies.
“There were plenty of other medications associated with brown fat activity in our large cohort,” Cohen notes. “This is just a start.”
Source: www.sciencedaily.com



